Lineage Cell Therapeutics, Inc.LCTX
What Lineage Cell Therapeutics, Inc. does.
We are a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. Certain diseases and medical events can arise from the loss of critical cellular activity and lead to devastating or difficult-to-treat conditions or impairments. Our work is grounded in the emerging evidence that replacing or supporting those cells that have become dysfunctional or “lost” (destroyed or dead) can restore or replenish normal function and improve treatment and recovery paradigms. We call this approach “Replace and Restore”. We believe cellular therapies aimed at entirely replacing dysfunctional or destroyed cells may have more durable, broader, or suitable applicability than traditional pharmaceutical products, which often seek to affect just a single molecular target or group of biological pathways. Transplantation of replacement cells represents an emerging branch of medicine, and we believe we are uniquely positioned to capitalize on its opportunities by demonstrating the value of administering mature, differentiated cells to patients. We are developing a portfolio of assets based on this mechanism and our most clinically-advanced program to date is OpRegen (RG6501), an allogeneic retinal pigmented epithelial (RPE) cell replacement therapy currently in Phase 2a development under a worldwide collaboration with F. Hoffman-La Roche Ltd. and Genentech, Inc., a member of the Roche Group (collectively or individually, “Roche” or “Genentech”), for the treatment of geographic atrophy (GA) secondary to dry-AMD.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.8M | $4.3M | $14.7M | $8.9M | $9.5M | $14.6M |
| Net income | -$20.6M | -$43.0M | -$26.3M | -$21.5M | -$18.6M | -$63.5M |
| Free cash flow | -$19.8M | -$23.9M | $646,000 | -$29.2M | -$23.7M | -$19.4M |
More on LCTX.
- Lineage Cell Therapeutics, Inc. summary
- Lineage Cell Therapeutics, Inc. financial statements
- Lineage Cell Therapeutics, Inc. key metrics
- Lineage Cell Therapeutics, Inc. health scores and style box
- Lineage Cell Therapeutics, Inc. earnings
- Lineage Cell Therapeutics, Inc. dividends
- Lineage Cell Therapeutics, Inc. valuation
- Lineage Cell Therapeutics, Inc. ownership and insiders
- Lineage Cell Therapeutics, Inc. peers
Figures from Lineage Cell Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.